ClinicalTrials.gg
CompletedNCT04921384SunriseUpdated Jan 14, 2026

Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine

A Phase 3 interventional study of Placebo and Eptinezumab in Migraine, sponsored by H. Lundbeck A/S. Completed at 87 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
981
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.

Enrollment
2nd of 21
981 · median 193
Started
2021
with 4 others
Phase 3
13 of 21
5 open now
Registered
11th of 21
by date
Lead sponsor
12 of 21
H. Lundbeck A/S

Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 2nd largest by enrollment, is one of 5 that started in 2021, is one of 13 in phase 3, and was the 11th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About eptinezumab

eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing eptinezumab in Migraine Disorders, or all of them as a file.
02

Study summary

This study evaluates the efficacy of eptinezumab to prevent migraine in participants with chronic migraine.

Read the detailed description

This is an interventional, multi-regional, multi-site, randomized, double-blind, placebo-controlled Phase III study, to confirm the efficacy and safety of eptinezumab in participants with chronic migraine who are eligible for preventive treatment.

participants will be randomly allocated to one of three treatment groups: eptinezumab 300 mg, eptinezumab 100 mg, or placebo.

The double-blind, placebo-controlled treatment period will be followed by an extension period where all participants will receive active treatment to further assess the safety and tolerability of eptinezumab.

The total study duration from the Screening Visit to the Safety Follow-up Visit is approximately 36 weeks and includes a Screening Period (28-30 days), a Placebo-controlled Period (12 weeks), an Extension Period (12 weeks), and a Safety Follow-up Period (8 weeks).

03

Conditions studied

  • Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has a diagnosis of CM as defined by IHS ICHD-3 guidelines confirmed at screening visit with a history of migraine onset at least 12 months prior to the Screening Visit.
  • The participant has a migraine onset at ≤50 years of age.
  • The participant has ≥8 migraine days per month for each month within the past 3 months prior to the Screening Visit.
  • The participant fulfils the following criteria for migraine in prospectively collected information in the eDiary during the screening period:
  • Migraine occurring on ≥8 days and headache occurring on ≥15 to ≤26 days.
  • The participant has demonstrated compliance with the Headache eDiary by entry of data for at least 24 of the 28 days following the Screening Visit.
  • The participant is aged ≥18 (≥20 for Taiwan) and ≤75 years at the Screening Visit.

Exclusion criteria

Exclusion Criteria:

  • The participant has received any medication targeting the calcitonin gene-related peptide (CGRP) pathway as preventive treatment of migraine.
  • The participant has confounding and pain syndromes, (for example, fibromyalgia, chronic low back pain, complex regional pain syndrome).
  • The participant has a diagnosis of acute or active temporomandibular disorder.
  • The participant has a history or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), ophthalmoplegic migraine, migraine with brainstem aura and migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration).
  • The participant has a lifetime history of psychosis, bipolar mania, or dementia.
  • Participants with other psychiatric conditions whose symptoms are not controlled or who have not been adequately treated for a minimum of 6 months prior to screening are also excluded.
  • The participant has a history of clinically significant cardiovascular disease, including uncontrolled hypertension, vascular ischaemia or thromboembolic events (for example, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism).

Other inclusion and exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
981 participants (actual)

Study arms

  • Experimental
    Eptinezumab 300 mg

    300 mg eptinezumab by intravenous (IV) infusion.

    Drug: Eptinezumab

  • Experimental
    Eptinezumab 100 mg

    100 mg eptinezumab by IV infusion.

    Drug: Eptinezumab

  • Placebo comparator
    Placebo

    Placebo by IV infusion.

    Drug: Placebo · Drug: Eptinezumab

Interventions

  • DrugPlacebo

    0.9% normal saline, intravenously

  • Solution for infusion, intravenously

    Also known as: Lu AG09221

06

What researchers measure

Primary outcomes

  1. Change from baseline in the number of monthly migraine days (MMDs) (Weeks 1-12)

    Time frame: Weeks 1-12

Secondary outcomes

  1. Response: ≥50% reduction from baseline in MMDs (Weeks 1-12)

    Time frame: Weeks 1-12

  2. Response: ≥75% reduction from baseline in MMDs (Weeks 1-4)

    Time frame: Weeks 1-4

  3. Response: ≥75% reduction from baseline in MMDs, (Weeks 1-12)

    Time frame: Weeks 1-12

  4. Migraine rate on the day after dosing

    Time frame: Day 1

  5. Response: ≥50% reduction from baseline in monthly headache days (MHDs) (Weeks 1-12)

    Time frame: Weeks 1-12

  6. Change from baseline in the number of MHDs (Weeks 1-12)

    Time frame: Weeks 1-12

  7. Response: ≥75% reduction from baseline in MHDs (Weeks 1-4)

    Time frame: Weeks 1-4

  8. Change from baseline in rate of migraines with severe pain intensity (Weeks 1-12)

    Time frame: Weeks 1-12

  9. Change from baseline in rate of headaches with severe pain intensity (Weeks 1-12)

    Time frame: Weeks 1-12

  10. Change from baseline in the number of MMDs with use of acute medication (Weeks 1-12)

    Time frame: Weeks 1-12

  11. Patient Global Impression of Change (PGIC) score at week 12

    Time frame: Week 12

  12. Most Bothersome Symptom (MBS) score at Week 12, as measured relative to Screening

    Time frame: Screening to Week 12

  13. Change from baseline to Week 12 in the Headache Impact Test (HIT-6) score

    Time frame: Baseline to Week 12

  14. Change from baseline to Week 12 in the Migraine-Specific Quality of Life (MSQ v2.1) sub-scores (Role Function-Restrictive, Role Function-Preventive, Emotional Function)

    Time frame: Baseline to Week 12

  15. Change from baseline to Week 12 in the Health-Related Quality of Life (EQ-5D-5L) Visual Analogue Scale (VAS) score

    Time frame: Baseline to Week 12

  16. Health Care Resources Utilization (HCRU)

    Migraine-specific healthcare resource utilization information will be collected in terms of outpatient health care professional visits, emergency room visits, hospital admissions, as well as duration of hospital stays.

    Time frame: Baseline to Week 12

  17. Change from baseline to Week 12 in the Work Productivity and Activity Impairment Questionnaire: Migraine (WPAI:M) sub-scores (Absenteeism, Presenteeism, Work productivity loss, Activity impairment)

    Time frame: Baseline to Week 12

07

Study locations

87 sites
  • The First Medical Center of The Chinese PLA General Hospital (301 Hospital)
    Beijing, Beijing Municipality 100853, China
  • The First Affiliated Hospital of Guangzhou Medical University - Yanjiang Campus
    Guangzhou, Guangdong 510120, China
  • People's Hospital of Zhengzhou
    Zhengzhou, Henan 450003, China
  • Renmin Hospital of Wuhan University - Main Campus
    Wuhan, Hubei 430060, China
  • Beijing Chaoyang Hospital Capital Medical University
    Beijing, 100020, China
  • Xuanwu Hospital Capital Medical University
    Beijing, 100053, China
  • The First Affiliated Hospital With Nanjing Medical University(Jiangsu Province Hospital)
    Beijing, 610041, China
  • The First Hospital of Jilin University
    Changchun, 130021, China
  • The Second Norman Bethune Hospital of Jilin University - Ziqiang Campus
    Changchun, 130022, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, 400016, China
  • The Affiliated Hospital of Guizhou Medical University
    Guiyang, 550000, China
  • Jiangxi Pingxiang People's Hospital
    Pingxiang, 337055, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, 430022, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, 710061, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, 450052, China
  • Malkhaz Katsiashvili Multiprofile Emergency Medicine Center -3 Nakalakevis Kucha
    Tbilisi, 0101, Georgia
  • Ltd Israel-Georgia Medical Research Clinic Helsicore
    Tbilisi, 0112, Georgia
  • Pineo Medical Ecosystem
    Tbilisi, 0114, Georgia
  • Aversi Clinic LTD
    Tbilisi, 0160, Georgia
  • MediClubGeorgia Ltd
    Tbilisi, 0160, Georgia
  • Multiprofile Clinic Consilium Medulla
    Tbilisi, 0186, Georgia
  • S. Khechinashvili University Clinic, Ltd.
    Tbilisi, 179, Georgia
  • Tokyo Dental College Ichikawa General Hospital
    Ichikawa-Shi, Chiba 272-0824, Japan
  • Nakamura Memorial Hospital
    Sapporo-Shi Chuo-Ku, Hokkaidô 060-0061, Japan
  • Iwate Medical University Uchimaru Medical Center
    Morioka, Iwate 020-8505, Japan
  • Sendai Headache and Cranial Nerves Clinic
    Sendai-Shi Taihaku-Ku, Miyagi 982-0014, Japan
  • Makabe Clinic
    Okayama-Shi Kita-Ku, Okayama-ken 700-0964, Japan
  • Saitama Neuropsychiatric Institute
    Saitama-shi, Saitama 338-8577, Japan
  • Moriyama Neurological Center Hospital
    Edogawa-ku, Tokyo 134-0085, Japan
  • Shinagawa strings clinic
    Minato-Ku, Tokyo 108-0075, Japan
  • USUDA CLINIC for internal medicine
    Setagaya-ku, Tokyo 156-0043, Japan
  • Fukuuchi Pain Clinic
    Shinjuku, Tokyo 160-0017, Japan
  • Keio University Hospital
    Shinjuku-Ku, Tokyo 160-8582, Japan
  • Suzuki Kei Yasuragi clinic
    Tachikawa-Shi, Tokyo 190-0001, Japan
  • Nagamitsu Clinic
    Hōfu, Yamaguchi 7470802, Japan
  • DOI Clinic Internal Medicine
    Hirosima Naka-ku, 730-0031, Japan
  • Atsuchi Neurosurgery Hospital
    Kagoshima, 892-0842, Japan
  • Ikeda Neurosurgical Clinic
    Kasuga, 816-0824, Japan
  • Jinnouchi Neurosurgery Clinic
    Kasuga-shi, 816-0802, Japan
  • Shin Matsudakai Atago Hospital
    Kochi, 780-0051, Japan
  • Tatsuoka Neurology Clinic
    Kyoto Shimojo-ku, 680-8811, Japan
  • Dokkyo Medical University Hospital
    Mibu-Machi, 321-0293, Japan
  • Mito Kyodo General Hospital
    Mito, 310-0015, Japan
  • Tominaga Hospital
    Naniwa-ku, 5560017, Japan
  • Tokyo headache clinic
    Shibuya-ku, 151-0051, Japan
  • Japanese Red Cross Shizuoka Hospital
    Shizuoka, 420-0853, Japan
  • Eiju General Hospital
    Taitō City, 110-8645, Japan
  • Kitasato University Kitasato Institute Hospital
    Tokyo, 108-8642, Japan
  • Toyota Memorial Hospital
    Toyota-shi, 471-8513, Japan
  • Solumed Centrum Medyczne
    Poznan, Greater Poland Voivodeship 60-101, Poland
  • Instytut Zdrowia Dr Boczarska-Jedynak Sp. z o.o. Sp. k.
    Oświęcim, Lesser Poland Voivodeship 32-600, Poland
  • ETG Lublin - PPDS
    Lublin, Lublin Voivodeship 20-412, Poland
  • ETG Zamosc - PPDS
    Zamość, Lublin Voivodeship 22-400, Poland
  • MTZ Clinical Research Powered by PRATIA - PPDS
    Warsaw, Masovian Voivodeship 02-172, Poland
  • ETG Neuroscience - PPDS
    Warsaw, Masovian Voivodeship 02-677, Poland
  • Centrum Medyczne Gdynia - PRATIA - PPDS
    Gdynia, Pomeranian Voivodeship 81-338, Poland
  • Centrum Medyczne Silmedic Sp z o o
    Katowice, Silesian Voivodeship 40-282, Poland
  • Centrum Medyczne Katowice - PRATIA - PPDS
    Katowice, 40-081, Poland
  • Centrum Medyczne Kiepury Clinic
    Sosnowiec, 41-209, Poland
  • MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak
    Wroclaw, 52-210, Poland
  • MUDr. Beata Dupejova, Neurologicka ambulancia, s.r.o.
    Banská Bystrica, 974 04, Slovakia
  • IN MEDIC, s.r.o.
    Bardejov, 085 01, Slovakia
  • KONZILIUM s.r.o
    Dubnica nad Váhom, 018 41, Slovakia
  • SANERA, s.r.o.
    Prešov, 080 01, Slovakia
  • Inje University Ilsan Paik Hospital
    Goyang-si, Gyeonggido 10380, South Korea
  • Chungnam National University Hospital
    Daejeon, 35015, South Korea
  • Hallym University Dongtan Sacred Heart Hospital
    Gyeonggi-do, 18450, South Korea
  • Nowon Eulji Medical Center, Eulji University
    Seoul, 01830, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Kangbuk Samsung Hospital
    Seoul, 03181, South Korea
  • Severance Hospital Yonsei University Health System
    Seoul, 03722, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Hospital Universitario Vall d'Hebron - PPDS
    Barcelona, 8035, Spain
  • C.H. Regional Reina Sofia - PPDS
    Córdoba, 14008, Spain
  • Hospital Universitari Arnau de Vilanova
    Lleida, 25198, Spain
  • Hospital Universitario La Paz - PPDS
    Madrid, 28046, Spain
  • Hospital Universitario HM Sanchinarro - CIOCC
    Madrid, 28050, Spain
  • Hospital Universitario Virgen Macarena
    Seville, 41009, Spain
  • Hospital Universitario Virgen del Rocio - PPDS
    Seville, 41013, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia
    Valencia, 46026, Spain
  • Hospital Clinico Universitario de Valladolid
    Valladolid, 47005, Spain
  • Hospital Clinico Universitario Lozano Blesa
    Zaragoza, 50009, Spain
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Tri-Service General Hospital
    Taipei, 11490, Taiwan
  • Chang Gung Memorial Hospital, Linkou
    Taoyuan City, 33305, Taiwan
08

References and documents

Publications

  • Yu S, Matsumori Y, Kim BK, Gryglas-Dworak A, Giorgadze G, Pozo-Rosich P, Krog Josiassen M, Ranc K, Ettrup A, Mittoux A, Sperling B, Takeshima T. Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial. Cephalalgia. 2025 Oct;45(10):3331024251386095. doi: 10.1177/03331024251386095. Epub 2025 Oct 15. PubMed 41091746 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Oct 2024, 40 months.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 40 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2021
First posted
Jun 10, 2021
StartActual
May 29, 2021
Primary completionActual
Oct 1, 2024
CompletionActual
Feb 17, 2025
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04921384
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Jun 10, 2021
Start date
May 29, 2021
Primary completion
Oct 1, 2024
Completion
Feb 17, 2025
Last update
Jan 14, 2026

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eptinezumab

Start the discussion